The aim of this study was to determine whether pretreatment expression levels of five immunohistochemical markers including p53, Bcl-2, APAF-1, VEGF and EGFR could predict complete pathologic tumour regression in patients with advanced rectal cancer undergoing preoperative radiotherapy. This evidence concerns the gene BCL2 and rectal cancer.